Targeted therapy aims to block signaling processes that sustain the proliferation or survival of the cancer cells [5], but for CRC, targeted therapy has so far narrowly focused on blocking the function of EGFR or angiogenesis, mostly using monoclonal antibodies against EGFR or VEGFR [6]. The gene discussed is KDR; the disease is cancer.